SCE-B
DR-ENJ-401
Approved small_molecule completed
Quick answer
SCE-B for Nocturnal Vasomotor Symptoms is a Approved program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Nocturnal Vasomotor Symptoms
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed